Page last updated: 2024-11-04

1-methyl-3-isobutylxanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methyl-3-isobutylxanthine, also known as caffeine, is a naturally occurring methylxanthine alkaloid found in various plants, including coffee beans, tea leaves, and cocoa beans. It is synthesized through a complex metabolic pathway in these plants. Caffeine is a stimulant that affects the central nervous system, increasing alertness, reducing fatigue, and enhancing cognitive function. It also has a diuretic effect and can elevate blood pressure. The compound's importance lies in its widespread consumption as a psychoactive substance and its impact on human health and behavior. Caffeine's effects on sleep, anxiety, and dependence are extensively studied. Research investigates its potential therapeutic benefits for treating conditions like Parkinson's disease and Alzheimer's disease. Caffeine's role in athletic performance and its interactions with various medications are also subjects of ongoing research.'
```

1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3758
CHEMBL ID275084
CHEBI ID34795
CHEBI ID43253
SCHEMBL ID50315
MeSH IDM0023168

Synonyms (184)

Synonym
MLS001066424
BRD-K94979336-001-06-9
AKOS003390599
gtpl388
KBIO1_000922
DIVK1C_000922
EU-0100642
3-isobutyl-1-methylxanthine, >=99% (hplc), powder
PDSP2_000322
[eur j pharmacol 170: 35 (1989)]
isobutylmethylxanthine
BIO1_000945
BIO1_001434
BIO1_000456
BIO2_000887
NCGC00015559-01
BIO2_000407
lopac-i-5879
IDI1_002162
IDI1_000922
BCBCMAP01_000110
1h-purine-2,6-dione, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-
3-isobutyl-1-methyl-7h-purine-2,6-dione
3-isobutyl-1-methylxanthine
CMAP_000087
PDSP1_000324
BSPBIO_001153
OPREA1_228781
3-isobutyl-1-methyxanthine
ibmx
IBM ,
wln: t56 bm dn fnvnvj f1y1&1 h1
nsc165960
1h-purine-2, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-
nsc-165960
28822-58-4
xanthine, 3-isobutyl-1-methyl-
3-isobutyl-1-methylxanthine, bioultra, >=99%
1ZKL
2HD1
1ZKN
BSPBIO_003558
OPREA1_135287
smr000326697
MLS001056732
NCGC00094009-06
NCGC00094009-02
NCGC00094009-05
1-methyl-3-isobutylxanthine
NCGC00094009-03
3,7-dihydro-3-isobutyl-1-methyl-1h-purine-2,6-dione
3-isobutyl 1-methylxanthine
ccris 4290
c10h14n4o2
einecs 249-259-3
methyl-isobutylxanthine
nsc 165960
KBIO2_005134
KBIO2_005629
KBIO3_003044
KBIO3_000906
KBIO2_000493
KBIOSS_002575
KBIO2_007702
KBIO3_002878
KBIOGR_000493
KBIOGR_002566
KBIO2_003061
KBIO2_002566
MOLMAP_000030
KBIOGR_001344
KBIOSS_000493
KBIO3_000905
SPECTRUM4_001052
SPECTRUM2_001705
SPECTRUM2_001735
SPBIO_001690
SPECTRUM3_001958
NINDS_000922
SPBIO_001810
SPECTRUM2300204
SPECTRUM1505298
HSCI1_000261
LOPAC0_000642
SPECTRUM5_001856
NCGC00094009-01
NCGC00094009-04
methylisobutylxanthine
2R8Q
bdbm15336
1-methyl-3-(2-methylpropyl)-3,7-dihydro-1h-purine-2,6-dione
1-methyl-3-(2-methylpropyl)-2,3,6,7-tetrahydro-1h-purine-2,6-dione
chembl275084 ,
CHEBI:34795 ,
CHEBI:43253
1-methyl-3-(2-methylpropyl)-7h-purine-2,6-dione
3-isobutyl-1-methyl-9h-xanthine
3-isobutyl-1-methyl-3,9-dihydro-1h-purine-2,6-dione
3-isobutyl-1-methyl-7h-xanthine
3-isobutyl-1-methyl-3,7-dihydro-1h-purine-2,6-dione
1-methyl-3-(2-methylpropyl)-3,9-dihydro-1h-purine-2,6-dione
3-isobuthyl-1-methylxanthine
NCGC00015559-02
HMS2090J10
HMS1990I15
I 5879
3ECN
NCGC00015559-11
DB07954
L001156
2-acetoxy-benzoic acid
3-isobutyl-methylxanthine
HMS1792I15
HMS1362I15
HMS502O04
HMS3262A05
1-methyl-3-(2-methylpropyl)-1,3,7-trihydropurine-2,6-dione
HMS2231C11
CCG-39624
CCG-39513
NCGC00015559-05
NCGC00015559-09
NCGC00015559-07
NCGC00015559-06
NCGC00015559-10
NCGC00015559-04
NCGC00015559-03
NCGC00015559-08
tbt296u68m ,
unii-tbt296u68m
FT-0615920
LP00642
AKOS015903085
S5836
3-isobutyl-1-methyl-1h-purine-2,6(3h,7h)-dione
HMS3369E16
HY-12318
CS-3361
SCHEMBL50315
3JWR
3QI4
3ITU
sc 2964
3-isobutyl-1-methyl-xanthine
sc-2964
NCGC00261327-01
tox21_500642
3-isobutyl-1-methylxantliine
J-640140
3-isobutyl-1-methylxanthine (ibmx)
3,7-dihydro-1-methyl-3-(2-methylpropyl)-1h-purine-2,6-dione
xanthine, 1-methyl-3-(2-methylpropyl)
HB3000
HMS3648O18
HMS3403I15
HMS3604D14
mfcd00005584
DTXSID0040549
1-methyl-3-isobutyl-xanthine
J-800144
bdbm50027176
AS-71134
1-methyl-3-(2-methylpropyl)-2,3,6,9-tetrahydro-1h-purine-2,6-dione
D71221
SR-01000075185-1
sr-01000075185
ibmx(nsc165960; sc2964)
STL558248
imx;isobutylmethylxanthine;methylisobutylxanthine;nsc165960;sc2964
3-isobutyl-1-methylxanthine - cas 28822-58-4
Q223093
SR-01000075185-6
BRD-K94979336-001-09-3
SDCCGSBI-0050622.P003
NCGC00015559-21
BCP13248
A876607
3-isobutyl-1-methylanxthine
BI164529
HY-12318G
CS-0626124
ibmx (gmp)
BP-58719
SY074708

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We conclude that the emetic side effect of xanthine bronchodilators results from the inhibition of one or more forms of PDE rather than from adenosine antagonism."( Mechanism for the emetic side effect of xanthine bronchodilators.
Howell, RE; Kinnier, WJ; Muehsam, WT, 1990
)
0.28
"This study investigated if and to what extent the acute toxic effect of Cyclosporin A on pancreatic Wistar rat B cells is reversible."( Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats.
Besch, W; Dunger, A; Hahn, HJ; Kauert, C; Kotzke, G; Laube, F; Radloff, E, 1986
)
0.27
"Our results show that the use of the current version of the SPOM system may have adverse effects on oocytes and blastocysts calling for optimized protocols for improving oocyte competence."( Simulated physiological oocyte maturation has side effects on bovine oocytes and embryos.
Callesen, H; Fontes, PK; Hyttel, P; Kadarmideen, HN; Nogueira, MFG; Pedersen, HS; Pihl, M; Razza, EM; Stroebech, L, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" As a whole the pharmacodynamic profile of isbufylline is promising and, in the clinical setting, this compound might exert enhanced antiasthma effects coupled to a low incidence of central and cardiovascular adverse effects."( Pharmacodynamic profile of isbufylline, a new antibronchospastic xanthine devoid of central excitatory actions.
Antonelli, T; Bacciarelli, C; Ballati, L; Beani, L; Borea, PA; Giachetti, A; Manzini, S; Meini, S, 1990
)
0.28

Compound-Compound Interactions

ExcerptReferenceRelevance
"This study demonstrates synergistic effects on Tac expression by interleukin 1 (IL-1) or tumor necrosis factor alpha (TNF alpha) in combination with the adenylate cyclase stimulator, forskolin (FK), as well as by IL-1 with TNF alpha in the human NK-like leukemic cell line YT."( Synergistic induction of interleukin 2 receptor (TAC) expression on YT cells by interleukin 1 or tumor necrosis factor alpha in combination with cAMP inducing agents.
Altman, A; Scholz, W, 1989
)
0.28

Bioavailability

ExcerptReferenceRelevance
" This may represent a therapeutic strategy for vascular diseases characterized by decreased bioavailability of NO."( Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity.
Barber, DA; Crotty, TB; Gloviczki, P; Katusic, ZS; Kullo, IJ; Mozes, G; O'Brien, T; Schwartz, RS, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" The dose-response effects of IBX on growth inhibition of malignant cells in mixed cultures appear to correlate well with its ability to elevate cAMP levels."( Modulation of cellular interactions between C3H/10T1/2 cells and their transformed counterparts by phosphodiesterase inhibitors.
Bertram, JS, 1979
)
0.26
" Dopamine and the GABAB receptor agonist baclofen both inhibited cyclic-AMP efflux and alpha-MSH release, with similar dynamics of inhibition and similar dose-response relationships."( Dynamics of cyclic-AMP efflux in relation to alpha-MSH secretion from melanotrope cells of Xenopus laevis.
de Koning, HP; Huchedé, B; Jenks, BG; Roubos, EW, 1992
)
0.28
" The presence of forskolin in the incubation medium resulted in significant upward shifts of the dose-response curves for both peptides."( Effects of brain-gut related peptides on cAMP levels in myenteric ganglia of guinea-pig small intestine.
Baidan, LV; Fertel, RH; Wood, JD, 1992
)
0.28
" The dose-response relationship for isoproterenol-stimulated generation of cAMP correlated with the dose-response relationship for isoproterenol-stimulated secretion of 35S-labeled molecules."( Bovine tracheal serous cell secretion: role of cAMP and cAMP-dependent protein kinase.
Basbaum, CB; Finkbeiner, WE; Hu, L; Widdicombe, JH, 1992
)
0.28
" This was seen as a 5-6-fold right shift in the dose-response curves for AVP action (cAMP accumulation in intact cells and AC stimulation in homogenates and isolated membranes) and in a decrease in the maximum effect of AVP on these parameters."( Desensitization of the human V2 vasopressin receptor. Homologous effects in the absence of heterologous desensitization.
Antaramian, A; Birnbaumer, M; Gilbert, S; Themmen, AP, 1992
)
0.28
" This observation suggests that the resting level of adenosine in our slices is appreciable, and an analysis of the adenosine dose-response relation is consistent with endogenous adenosine levels of about 10 microM."( Adenosine decreases neurotransmitter release at central synapses.
Prince, DA; Stevens, CF, 1992
)
0.28
" Prostaglandins E1 or E2, vasoactive intestinal peptide, carbachol, phenylephrine, or platelet-activating factor did not affect either the maximal cAMP response or the isoproterenol dose-response relationship."( Beta-adrenergic receptors on human tracheal epithelial cells in primary culture.
Davis, PB; Infeld, M; Kercsmar, CM; Silski, CL, 1990
)
0.28
", norepinephrine dose-response curves were shifted to left in presence of adenosine deaminase or IBMX and to right with 2-chloroadenosine)."( Cold acclimation induces desensitization to adenosine in brown fat cells without changing receptor binding.
Mohell, N; Nedergaard, J; Unelius, L, 1990
)
0.28
" Upon pretreatment with morphine over greater than or equal to 12 h, a fourfold shift of the PGE1-morphine dose-response curve was observed, whether or not IBMX was added."( Regulation of cyclic AMP by the mu-opioid receptor in human neuroblastoma SH-SY5Y cells.
Duan, DS; Eiger, S; Lameh, J; Sadée, W; Yu, VC, 1990
)
0.28
" Dose-response studies reveal that 10(-6) to 10(-4) M concentrations of 8-bromo-cAMP (8-Br-cAMP) elicit a maximal response."( Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors.
Aronica, SM; Katzenellenbogen, BS, 1991
)
0.28
" Both milrinone and pertussis toxin shifted the blood pressure dose-response curves of B-HT 920 to the right, but the responses to angiotensin II were decreased after milrinone pretreatment only."( Cardiovascular responses to milrinone in pertussis toxin-pretreated pithed rats.
De Wildt, DJ; Porsius, AJ; Van Rooij, HH; Verrijk, R; Wemer, J, 1990
)
0.28
" An insulin dosage as low as 10(-10) M was inhibitory to PEPCK activity, suggesting the involvement of insulin receptors."( Insulin and other regulatory factors modulate the growth and the phosphoenolpyruvate carboxykinase (PEPCK) activity of primary rabbit kidney proximal tubule cells in serum free medium.
Taub, M; Wang, Y, 1991
)
0.28
" The non-selective phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) (1 mM) resulted in a more severe suppression of the histamine and pilocarpine responses and also produced a significant suppression of the maximal response to oxotremorine and a small shift in the carbachol dose-response curve."( Beta-adrenoceptor induced inhibition of muscarinic receptor-stimulated phosphoinositide metabolism is agonist specific in bovine tracheal smooth muscle.
Chilvers, ER; Nahorski, SR; Offer, GJ, 1991
)
0.28
" Under essentially identical conditions, the dose-response curve for IPR stimulation of AC activity in the absence of 3-isobutyl-1-methylxanthine was similar in trained and control rats."( Enhanced coupling of adenylate cyclase to lipolysis in permeabilized adipocytes from trained rats.
Izawa, T; Komabayashi, T; Mochizuki, T; Suda, K; Tsuboi, M, 1991
)
0.28
" In contrast, PR mRNA in the K3 subline, as in the parental K1 cells, is still up-regulated by E2, and ER mRAN content and the ER mRNA transcription rate are still down-regulated by E2 and show normal E2 dose-response relationships, implying that the ER in this subline is functional."( Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines.
Cho, HS; Katzenellenbogen, BS; NG, PA, 1991
)
0.28
" In the present investigation we studied the pH dependency and dose-response effects of suramin on islet lysosomal enzyme activities as well as the effect of suramin treatment on the insulin-secretory response to various secretagogues in mice."( Effect of the lysosomotropic drug suramin on islet lysosomal enzyme activities and the insulin-secretory response induced by various secretagogues.
Lundquist, I; Panagiotidis, G; Salehi, AA, 1991
)
0.28
" The dose-response curve for vasopressin-sensitive Pf showed the Km to be 1 microU ml-1."( Modulation of vasopressin-induced water permeability of the cortical collecting tubule by endogenous and exogenous prostaglandins.
Stokes, JB, 1985
)
0.27
" The VIP/PHM-27 gene dosage was unchanged by Bt2cAMP and phorbol esters."( Synergistic stimulation of VIP/PHM-27 gene expression by cyclic AMP and phorbol esters in human neuroblastoma cells.
Hayakawa, Y; Nishizawa, M; Ohsawa, K; Okamoto, H; Yamagami, T; Yamamoto, H; Yanaihara, N, 1985
)
0.27
" A dose-response study showed that FSH pretreatment produced three separate effects on Sertoli cell steroidogenesis: an increased basal production of estrogen; a decreased maximal response when doses of 10 ng/ml FSH or higher were employed in the preincubation; and a decreased sensitivity of the Sertoli cell to FSH."( Effect of phosphodiesterase inhibitors on Sertoli cell refractoriness: reversal of the impaired androgen aromatization.
Conti, M; Geremia, R; Monaco, L; Stefanini, M, 1986
)
0.27
" Both peptides shifted the FSH dose-response curve to the left, making the cells more sensitive to this gonadotropin."( Stimulation of adenosine 3',5'-monophosphate production in rat Sertoli cells by alpha-melanotropin-stimulating hormone (alpha MSH) and des-acetyl alpha MSH.
Bardin, CW; Boitani, C; Mather, JP, 1986
)
0.27
" Dose-response curves for MIX potentiation of cAMP-stimulated glycogenolysis and for MIX inhibition of the effects of insulin on cAMP-stimulated glycogenolysis suggested that at higher concentrations (250 microM) MIX may act at a site other than phosphodiesterase inhibition."( Methylisobutylxanthine blocks insulin antagonism of cAMP-stimulated glycogenolysis at a site distinct from phosphodiesterase. Evidence favoring an insulin-insensitive calcium release mechanism.
Gabbay, RA; Lardy, HA, 1986
)
0.27
" No study showed a clear-cut dose-response relationship."( Accumulation of cyclic 3',5'-adenosine monophosphate in cultured neonatal human dermal fibroblasts exposed to parathyroid hormone and prostaglandin E2.
Fritz, SR; Fryer, MJ; Heath, H, 1986
)
0.27
" At peptide concentrations of 1 microM clear-cut plateaus of the dose-response curves are not yet reached."( Atrial natriuretic hormones raise the level of cyclic GMP in neural cell lines.
Friedl, A; Hamprecht, B; Harmening, C, 1986
)
0.27
" The dose-response curve for carbachol was biphasic."( Stimulation of acid formation by histamine, carbachol and pentagastrin in isolated pig parietal cells.
Ljungström, M; Mårdh, S; Norberg, L; Vega, FV, 1986
)
0.27
" Analysis of the forskolin dose-response kinetics indicated a dose-dependent increase in the accumulation of cAMP."( Evaluation of the effects of forskolin and the antilipolytic agents insulin and nicotinic acid on cyclic AMP levels in rat epididymal adipocytes.
Fatemi, SH, 1986
)
0.27
" A close dose-response relationship existed for forskolin and for cholera toxin between cAMP generation and carcinoembryonic antigen release."( Effects of cyclic adenosine 3':5'-monophosphate upon glycoprotein and carcinoembryonic antigen synthesis and release by human colon cancer cells.
Hwang, WI; Kim, YS; Sack, TL, 1986
)
0.27
" The dose-response curves were broad and each peptide accelerated dissociation of bound 125I-CGRP."( Mechanism of action of calcitonin gene-related peptide in stimulating pancreatic enzyme secretion.
Gardner, JD; Jensen, RT; Jones, SW; Noguchi, M; Villanueva, ML; Zhou, ZC, 1986
)
0.27
" Neither xanthine shifted the calcium dose-response when PMNs were activated with calcium ionophore."( Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation.
Crowley, JJ; Cusack, BJ; Nielson, CP; Vestal, RE, 1986
)
0.27
" In dose-response curves, the isoproterenol-sensitive K+ efflux was half-maximally inhibited (IC50) with 2-5 X 10(-10) M of isoproterenol concentration."( Stimulation of beta-adrenoceptors inhibits calcium-dependent potassium-channels in mouse macrophages.
Braquet, P; Dausse, JP; Garay, R; Hannaert, P; Rosati, C, 1986
)
0.27
" Amrinone relaxed the strips precontracted by KCl, norepinephrine, serotonin or STA2 in a dose-dependent manner, and it shifted the dose-response curves downward."( Involvement of cyclic AMP in vasodilatation by amrinone: a comparative study with 3-isobutyl-methyl-xanthine (IBMX).
Kishi, Y; Numano, F, 1986
)
0.27
" Thus, palytoxin exhibited a biphasic dose-response curve for enhanced bone resorption, with stimulation at low concentrations (0."( Palytoxin: an extraordinarily potent stimulator of prostaglandin production and bone resorption in cultured mouse calvariae.
Fujiki, H; Lazzaro, M; Levine, L; Tashjian, AH, 1987
)
0.27
" The dose-response relationships for enoximone were always less steep than those for IBMX."( Effects of enoximone and isobutylmethylxanthine on contractile tension and cyclic nucleotide levels in isolated blood-perfused dog papillary muscle.
Dage, RC; Hsieh, CP; Kariya, T; Ruberg, SJ, 1987
)
0.27
" However, comparison of the dose-response curves for the actions of prostaglandins on pepsinogen secretion and cAMP revealed that detectable increases in cAMP occurred with concentrations of these agents that were about ten-fold greater than those needed to stimulate pepsinogen secretion."( Relation of prostaglandin-induced increases in cellular cAMP to stimulation of pepsinogen secretion from dispersed chief cells.
Cosowsky, L; Raufman, JP, 1987
)
0.27
" The dose-response curve of the potassium response followed classical Michaelis-Menten kinetics."( Further characterization of the slow muscarinic responses in Xenopus oocytes.
Cohen, S; Dascal, N, 1987
)
0.27
"On isolated electrically stimulated left and spontaneously beating right guinea-pig atria the interaction between PDE-inhibitors and the positive inotropic and chronotropic action of orciprenaline, forskolin and histamine in dose-response curve was examined."( Interaction of phosphodiesterase inhibitors triamterene, papaverine, theophylline, IBMX and amrinone with other positive inotropic acting substances on isolated guinea-pig atria.
Greeff, K; Schmitt, M, 1987
)
0.27
" The dose-response curve for cyclic AMP on ICa was well fitted by the Michaelis equation with a K50 (i."( Cyclic guanosine 3',5'-monophosphate regulates the calcium current in single cells from frog ventricle.
Fischmeister, R; Hartzell, HC, 1987
)
0.27
" The magnitude of antiviral activity induced by IFN-beta and IFN-gamma was similar in differentiated and undifferentiated 3T3-L1 cells, although the slopes of the dose-response curves were different; IFN-gamma induced an antiviral state with greater efficiency than IFN-beta in differentiated and undifferentiated 3T3-L1 cells."( Antiviral and antidifferentiative activities of interferon beta and gamma in relation to their induction of double-stranded RNA-dependent protein kinase activity in 3T3-L1 cells.
Grossberg, SE; Samuel, CE; Taylor, JL, 1988
)
0.27
" For rat CGRP and human CGRP, the dose-response curves for binding of 125I-CGRP were broad, and both peptides accelerated the rate of dissociation of bound 125I-CGRP."( Characterization of receptors for calcitonin gene-related peptide on gastric smooth muscle cells.
Collins, SM; Gardner, JD; Jensen, RT; Maton, PN; Sutliff, VE; Zhou, ZC, 1988
)
0.27
"1 mg/kg) enhanced clonidine-induced hypothermia and hypoactivity, chronic dosing (twice daily for 14 days) with desipramine (10 mg/kg) or rolipram (5 mg/kg) antagonized these behavioural effects."( Effect of long-term rolipram administration on the sensitivity of alpha 2-adrenoceptors in rat brain.
Luscombe, DK; Mustafa, MR; Stolz, JF, 1988
)
0.27
" MIX at 100 microM potentiated the effects of submaximal doses of isoproterenol and shifted the dose-response curve for cAMP to the left but did not affect the dose-response curve for 8-bromo-cAMP."( Role of phosphodiesterase in regulation of calcium current in isolated cardiac myocytes.
Hartzell, HC; Simmons, MA, 1988
)
0.27
" Differential actions of these agents on the dose-response curves for secretin- and VIP-induced increases in cAMP suggest that chief cell receptors for these peptides are coupled to pools of cAMP that are acted upon by heterogeneous phosphodiesterases with varying sensitivities to inhibitors."( Differential actions of phosphodiesterase inhibitors on secretin- and vasoactive intestinal peptide-induced increases in chief cell cAMP.
Cosowsky, L; Raufman, JP, 1988
)
0.27
" Pretreatment of ROS cells for 2 days with the glucocorticoid triamcinolone acetonide (TRM), shifted the dose-response curve for PKA activation by PTH upward compared to the control value."( Glucocorticoids and 1,25-dihydroxyvitamin D3 regulate parathyroid hormone stimulation of adenosine 3',5'-monophosphate-dependent protein kinase in rat osteosarcoma cells.
Catherwood, BD; Lorang, MT; Rubin, JE; Titus, L, 1988
)
0.27
" First, when the dose-response curve of PTH-induced ODC activity is compared with that of PTH-stimulated cAMP production, the ED50 for cAMP production is about five times as high as that for the induction of ODC activity."( Induction of ornithine decarboxylase activity in isolated chicken osteoblasts by parathyroid hormone: the role of cAMP and calcium.
Herrmann-Erlee, MP; Löwik, CW; Olthof, AA; van Leeuwen, JP; van Zeeland, JK, 1988
)
0.27
" The dose-response curves of the strips from both strains for alpha-adrenoceptor stimulation with NA determined after pretreatment with CTX were comparable to those determined in the absence of timolol."( Role of stimulatory GTP-binding protein (Gs) in reduced beta-adrenoceptor coupling in the femoral artery of spontaneously hypertensive rats.
Asano, M; Masuzawa, K; Matsuda, T, 1988
)
0.27
" However, the inhibitory dose-response curves of adenylate cyclase to R-PIA, nicotinic acid, GTP, guanylylimidodiphosphate, and guanosine 5'-O-(3-thiotriphosphate) were unaltered by adrenalectomy, indicating that the inhibitory function of Gi is unimpaired by adrenalectomy."( Role of adenosine 3',5'-monophosphate and the Ri-receptor Gi-coupled adenylate cyclase inhibitory pathway in the mechanism whereby adrenalectomy increases the adenosine antilipolytic effect in rat fat cells.
de Mazancourt, P; Giot, J; Giudicelli, Y; Lacasa, D, 1989
)
0.28
" SCH23390 (3-30 nmol), a selective D-1 DA receptor antagonist, caused a progressive parallel shift to the right in the dose-response curve for DA-induced pancreatic secretion without changes in the maximal response."( Do D-1 dopamine receptors mediate dopamine-induced pancreatic exocrine secretion in anesthetized dogs?
Chiba, S; Horiuchi, A; Iwatsuki, K; Yonekura, H, 1989
)
0.28
" The ATPase log dose-response curve was linear between approximately 12."( Enzyme activation of human prolactin: a potential basis for a bioassay.
Bertrand, PV; Ryle, M, 1989
)
0.28
" Dose-response experiments revealed that insulin stimulated D-glucose transport and 2-deoxyglucose uptake between 10(-11) and 10(-7) M with a maximal four- to sixfold stimulation."( Stimulation of glucose transport by insulin and norepinephrine in isolated rat brown adipocytes.
Bukowiecki, LJ; Marette, A, 1989
)
0.28
" Moreover, PDBu, which causes attenuation of the maximal response to vasoactive intestinal polypeptide (VIP), also induced a small right shift in the dose-response curve for VIP-induced cyclic AMP accumulation."( Regulation of GH3 pituitary tumour-cell adenylate cyclase activity by activators of protein kinase C.
Brown, BL; Dobson, PR; Quilliam, LA, 1989
)
0.28
" Methylene blue also caused 10 fold and 100 fold rightward shifts in the dose-response curves of MY-5445 and vinpocetine, respectively."( Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.
Brazdil, R; Diocee, BK; Jordan, R; Souness, JE, 1989
)
0.28
" The naltrexone stimulus-generalization curve and dose-response curve for loss of body weight were shifted to the left by IBMX and Ro 20-1724, which produce quasi-withdrawal, but not by papaverine, which does not."( Phosphodiesterase inhibitors potentiate opiate-antagonist discrimination by morphine-dependent rats.
Holtzman, SG, 1989
)
0.28
" Imipramine and nortriptyline also caused a rightward shift in the dose-response curve of histamine-induced cAMP generation."( Tricyclic antidepressants and acid secretory response of rabbit gastric cells.
Batzri, S, 1985
)
0.27
" Thus (-)-baclofen (100 microM) shifted the dose-response curve to forskolin to the right 5 fold in an apparently parallel fashion."( GABAB receptor modulation of adenylate cyclase activity in rat brain slices.
Hill, DR, 1985
)
0.27
" The dose-response curve was steep, nearly all incorporation being inhibited by 2 x IC50."( Inhibition of lymphocyte transformation by mepacrine and chloroquine.
Trist, DG; Weatherall, M, 1981
)
0.26
" The facilitative interaction between E2 and FSH could not be accounted for by mitogenic effects, by a leftward shift in the dose-response curves for FSH or E2, or by catabolism of progesterone to 20 alpha-hydroxypregn-4-en-3-one."( The role of estradiol as a biological amplifier of the actions of follicle-stimulating hormone: in vitro studies in swine granulosa cells.
Hammond, JM; Klase, PA; Strauss, JF; Veldhuis, JD, 1982
)
0.26
" IBMX by itself, stimulated ornithine decarboxylase (ODC) activity in a dose-response fashion; but the IBMX at concentrations up to 1 mM had no effect on the magnitude of the prolactin-stimulated ODC activity."( Effect of 3-isobutyl-1-methylxanthine on prolactin actions on RNA synthesis, casein synthesis, lipid synthesis and ornithine decarboxylase activity in mouse mammary gland explants.
Rillema, JA; Wing, LY, 1982
)
0.26
" With IBMX the dose-response curve for the stimulation of amylase secretion caused by VIP or secretin spanned a range of lower concentrations than did that obtained with Ro 20-1724, which in turn spanned a range of lower concentrations than did that obtained with theophylline."( Effects of inhibitors of cyclic nucleotide phosphodiesterase on the actions of vasoactive intestinal peptide and secretin on pancreatic acini.
Gardner, JD; Korman, LY; Sutliff, VE; Walker, MD, 1982
)
0.26
"5 mM-IBMX, the 2-chloroadenosine dose-response curve was shifted to the right two orders of magnitude."( Adenosine-elicited accumulation of adenosine 3', 5'-cyclic monophosphate in the chick embryo retina.
de Mello, FG; Paes de Carvalho, R, 1982
)
0.26
" Similar dose-response curves for cyclic AMP production were obtained."( Catecholamine stimulation of testosterone production via cyclic AMP in mouse Leydig cells in monolayer culture.
Cooke, BA; Dix, CJ; Golding, M; Hunter, MG, 1982
)
0.26
" The order of potency and effective dosage range to induce the behavioral alterations were, in descending order, rolipram (0."( Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors.
Wachtel, H, 1982
)
0.26
" This study serves to quantitate the pharmacologic effects of several agents on anti-IgE-mediated histamine release from dispersed human lung mast cells and has further suggested that the dispersed cell system is similar to the standard chopped lung system in dose-response relationships, kinetics, and pharmacologic modulation."( Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments.
Lichtenstein, LM; MacGlashan, DW; Newball, HH; Peters, SP; Schleimer, RP; Schulman, ES, 1982
)
0.26
" In dose-response studies with the cAMP analog, dibutyryl cyclic AMP (dbcAMP), we found that the RPE pigment did not exhibit intermediate states of aggregation with increasing concentrations of dbcAMP but instead changed abruptly from the fully light-adapted to the fully dark-adapted retinomotor positions between 10 microM and 50 microM exogenous dbcAMP concentrations."( Retinomotor pigment migration in the teleost retinal pigment epithelium. II. Cyclic-3',5'-adenosine monophosphate induction of dark-adaptive movement in vitro.
Basinger, S; Burnside, B, 1983
)
0.27
" In contrast, membranes from nervous mice and their littermates showed similar PIA dose-response curves."( Adenosine A1 receptors are associated with cerebellar granule cells.
Neff, NH; Wojcik, WJ, 1983
)
0.27
" Atropine (100 microM) produced a rightward shift of the dose-response curve, indicating the presence of a muscarinic receptor."( Regulation of pepsinogen release from canine chief cells in primary monolayer culture.
Amirian, DA; Ayalon, A; Sanders, MJ; Soll, AH, 1983
)
0.27
" IBMX but not Ro 20-1724 caused a parallel rightward shift in the dose-response curve for the stimulation of amylase secretion caused by carbachol."( Effects of inhibitors of cyclic nucleotide phosphodiesterase on actions of cholecystokinin, bombesin, and carbachol on pancreatic acini.
Gardner, JD; Jensen, RT; Sutliff, VE; Walker, MD, 1983
)
0.27
" Significantly, the dose-response curves for isoproterenol stimulation of lipolysis and respiration were both shifted by adenosine to higher agonist concentrations by the same order of magnitude, providing additional evidence for a tight coupling between lipolysis and respiration."( Control of brown adipose tissue lipolysis and respiration by adenosine.
Bukowiecki, LJ; Szillat, D, 1983
)
0.27
" The dose-response relationship for a cholinergic agonist, carbamylcholine, or an adrenergic agonist, norepinephrine, was unaffected by the presence of either 8-Br-cGMP or Bt2cGMP in the medium."( Evidence against a role for guanosine 3',5'-cyclic monophosphate in rat submandibular salivary gland potassium release.
Barzen, KA; Lafferty, JL; Quissell, DO, 1983
)
0.27
" The dose-response curves to ACh showed nonparallel increases in H+ secretion and histamine release."( Evidence for a direct action of acetylcholine on the gastric oxyntic cell of the amphibian.
Michelangeli, F; Ruiz, MC, 1984
)
0.27
" Dose-response curves and kinetics of inhibition were identical to those obtained in cultures stimulated by combinations of growth factors that do not increase the intracellular level of cAMP."( Cyclic AMP does not mediate inhibition of DNA synthesis by interferon in mouse Swiss 3T3 cells.
Ebsworth, NM; Rozengurt, E; Taylor-Papadimitriou, J, 1984
)
0.27
" The dose-response curves of induction of HGF secretion by cholera toxin and forskolin were nearly parallel with those of the intracellular cAMP levels."( Expression of hepatocyte growth factor is up-regulated through activation of a cAMP-mediated pathway.
Gohda, E; Iwao, M; Kataoka, H; Matsunaga, T; Takebe, T; Wu, YL; Yamamoto, I, 1994
)
0.29
" The content of cAMP in MIN6 cells was also elevated significantly by genistein and the dose-response relationship between the genistein and cAMP accumulation was consistent with the relationship between the genistein and insulin release."( Genistein augments cyclic adenosine 3'5'-monophosphate(cAMP) accumulation and insulin release in MIN6 cells.
Ishii, C; Ito, Y; Kato, N; Kawazu, S; Ohno, T; Shimizu, M; Tomono, S, 1993
)
0.29
" Dose-response curves of the inhibition of phosphate transport in response to PTH were identical in the presence or absence of U-73,122."( Effect of U-73,122, an inhibitor of phospholipase C, on actions of parathyroid hormone in opossum kidney cells.
Baldassare, JJ; Gonzalez, EA; Jacob, AK; Khan, M; Martin, KJ; McConkey, CL, 1994
)
0.29
" Individual histamine dose-response curves were shifted to the right by increasing ranitidine and cimetidine concentrations (0."( Secretagogue-induced [14C]aminopyrine uptake in isolated equine parietal cells.
Campbell-Thompson, M, 1994
)
0.29
" When dose-response curves for the phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX) were compared using perforated-patch vs."( Perforated-patch recording does not enhance effect of 3-isobutyl-1-methylxanthine on cardiac calcium current.
Kawamura, A; Wahler, GM, 1994
)
0.29
" Caffeine shifted the dose-response curves of the [Ca2+]i rise induced by vasopressin (0."( Caffeine inhibits cytosolic calcium oscillations induced by noradrenaline and vasopressin in rat hepatocytes.
Berthon, B; Claret, M; Combettes, L, 1994
)
0.29
" The ADR dose-response curve is significantly shifted to the right when cells were preincubated with the unspecific phosphodiesterase inhibitor IBMX."( Study of the activation mechanism of adriamycin on rat mast cells.
Botana, LM; Estévez, MD; Vieytes, MR, 1994
)
0.29
" Moreover, the soluble guanylate cyclase inhibitor LY-83583 inhibited in a dose-response manner the effects of the NO donors."( The nitric oxide donors, azide and hydroxylamine, inhibit the programmed cell death of cytokine-deprived human eosinophils.
Beauvais, F; Dubertret, L; Michel, L, 1995
)
0.29
" Dose-response and structure-activity relationships were consistent with a process mediated by interaction of TCDD with the Ah receptor."( Inhibition of 3T3-L1 adipose differentiation by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Enan, E; Liu, PC; Matsumura, F; Phillips, M, 1995
)
0.29
" The PKC activator TPA amplifies the response of mast cells to human GRF, shifting the dose-response curve to the left."( Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release.
Alfonso, A; Botana, LM; Estévez, MD; Louzao, MC; Vieytes, MR, 1995
)
0.29
" Stimulatory effects of injected caffeine were lower in chronically treated mice and the biphasic dose-response (stimulatory followed by depressant) curve for injected caffeine was left shifted."( Locomotor activity in mice during chronic treatment with caffeine and withdrawal.
Daly, JW; Jacobson, KA; Nikodijević, O, 1993
)
0.29
" This inhibition reflects the ability of GnRH to shift the CNP dose-response curve rightward (increasing the EC50 for CNP action approximately 10-fold both with and without 3-isobutyl-1-methylxanthine)."( Cyclic guanosine monophosphate production in the pituitary: stimulation by C-type natriuretic peptide and inhibition by gonadotropin-releasing hormone in alpha T3-1 cells.
Käppler, K; McArdle, CA; Poch, A, 1993
)
0.29
" However, the dose-response curve for pentagastrin in the presence of ranitidine plus IBMX was similar to that obtained in the absence of IBMX."( Gastrin action on aminopyrine accumulation in isolated pig parietal cells requires cAMP.
Cabero, JL; Li, ZQ; Mårdh, S, 1993
)
0.29
" Dose-response curves for the inhibition of ROS phagocytosis by forskolin and isoproterenol demonstrated that this process is exquisitely sensitive to these agonists, with an IC50 for these drugs of 33 nmol/l."( The phagocytosis of rod outer segments is inhibited by drugs linked to cyclic adenosine monophosphate production.
Abrams, TA; Hall, MO; Mittag, TW, 1993
)
0.29
" When the latter dosage of mifepristone (50 microM) was added 4h after LH+IBMX, no inhibitory effect was seen (17."( Inhibitory effect of mifepristone (RU 486) on ovulation in the isolated perfused rat ovary.
Brännström, M, 1993
)
0.29
" The characteristics of individual dose-response curves were compared according to the breed, season of birth and testicular weight of the lambs."( Secretion of transferrin in ovine seminiferous tubule cell cultures in response to FSH: influence of breed, season of birth and age of lambs.
Fontaine, I; Monet-Kuntz, C, 1993
)
0.29
" Dose-response experiments showed that insulin at a concentration of 1 nM was sufficient for the PI(3,4,5)P3 response."( The 3-phosphorylated phosphoinositide response of 3T3-L1 preadipose cells exposed to insulin, insulin-like growth factor-1, or platelet-derived growth factor.
Lin, Y; Pardasani, D; Sorisky, A, 1996
)
0.29
" Dose-response curves plotted as percentage change from baseline versus concentration of drug were determined for acetylstrophanthidin, isoproterenol, isobutylmethylxanthine, and milrinone."( Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium.
Bruce, E; Flemmal, K; Grossman, W; Gutstein, DE; Gwathmey, JK; Markis, JE; Morgan, JP; Ransil, BJ; Travers, KE, 1996
)
0.29
" The results were as follows: H-89 interfered with forskolin or IBMX arrested oocytes in dose-response manner (IBMX ED50 = 41 microM for COCs; forskolin ED50 = 9 microM for denuded oocytes)."( Roles of protein kinase A and C in spontaneous maturation and in forskolin or 3-isobutyl-1-methylxanthine maintained meiotic arrest of bovine oocytes.
Bavister, BD; Rose-Hellekant, TA, 1996
)
0.29
" Glucose dose-response studies show that both engineered and non-engineered lines respond maximally to submillimolar concentrations of glucose and that betaG 49/206 cells are the most sensitive to low concentrations of the hexose, consistent with their clearly elevated rate of [5-3H]glucose usage."( Regulation of insulin secretion from novel engineered insulinoma cell lines.
BeltrandelRio, H; Clark, SA; Henkel-Rieger, R; Hohmeier, HE; Newgard, CB; Normington, K, 1997
)
0.3
" Dose-response curves for both adrenergic agonists showed that HC increased linearly as a function of the log of the isoproterenol and epinephrine concentration."( Effect of beta-adrenergic agonists on paracellular width and fluid flow across outflow pathway cells.
Alvarado, JA; Chen, J; Franse-Carman, L; Murphy, CG; Underwood, JL, 1998
)
0.3
" Comparative dose-response curves indicated that maximal hormone-stimulated cAMP accumulation was 11- and 24-fold higher in human and rat cells, compared with cAMP production obtained in corresponding membranes, respectively."( Comparative involvement of cyclic nucleotide phosphodiesterases and adenylyl cyclase on adrenocorticotropin-induced increase of cyclic adenosine monophosphate in rat and human glomerulosa cells.
Côté, M; Gallo-Payet, N; Guillon, G; Payet, MD; Rousseau, E, 1999
)
0.3
" The dose-response curve to norepinephrine was shifted to the left in intact vessels compared with strips of vessels in the muscle bath, which suggests that whole vessels were more sensitive to norepinephrine."( Vascular smooth muscle mechanics in isolated perfused segments of carotid arteries.
Bagwell, CA; Beall, A; Brophy, C; Jerius, H; Karolyi, D, 2000
)
0.31
" alpha-MSH peptides were found to inhibit the stimulated GPx activity and had biphasic dose-response curves."( Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines.
Cartledge, S; Ghanem, G; Haycock, JW; MacNeil, S; Morandini, R; Rennie, IG; Rowe, SJ; Wyatt, A, 2000
)
0.31
" The levels of activin betaA and ActRIIA receptor mRNA elevated with increasing dose of hCG; however, the effect significantly decreased at dosage higher than 15 IU/ml."( Gonadotropin regulation of activin betaA and activin type IIA receptor expression in the ovarian follicle cells of the zebrafish, Danio rerio.
Ge, W; Pang, Y, 2002
)
0.31
" Moreover, ACh and Ca(2+) dose-response studies showed that accumulation of cAMP shifted the dose-response curves to the low concentration side, suggesting that it increases Ca(2+) sensitivity in the fusion of the exocytotic cycle."( cAMP modulation of Ca(2+)-regulated exocytosis in ACh-stimulated antral mucous cells of guinea pig.
Fujiwara, S; Imai, Y; Katsu, K; Kojima, K; Nakahari, T; Shimamoto, C, 2002
)
0.31
" Insulin responsiveness of the lipolytic and lipogenic pathways was analyzed by dose-response experiments, giving evidence for the involvement of improved insulin responsiveness in the enhanced lipogenic and reduced lipolytic activities of adipocytes in early pregnancy."( Fat accumulation in the rat during early pregnancy is modulated by enhanced insulin responsiveness.
Cacho, J; Crespo-Solans, MD; del Campo, S; Herrera, E; Ramos, MP, 2003
)
0.32
" With the current data the focus is on a time-course experiment; however, the proposed methods can easily be implemented on a dose-response experiment, or any other microarray experiment that contains a continuous variable of interest."( Empirical bayes gene screening tool for time-course or dose-response microarray data.
Burgoon, LD; Chinchilli, VM; Eckel, JE; Gennings, C; Zacharewski, TR, 2004
)
0.32
" This cytokinesis block assay applied specifically at the root elongation stage was then used to examine dose-response relationships in Japanese cedar seeds irradiated either acutely with X-rays or chronically with γ-rays."( Cytokinesis block micronucleus assay in field plants for monitoring radiation-induced genotoxicity of the environment.
Fuma, S; Ichikawa, S; Kouichi, M; Kubota, M; Kubota, Y; Watanabe, Y; Yoshida, S, 2014
)
0.4
" Last, OMP also steepens the dose-response relation to improve concentration coding although at the cost of losing responses to weak stimuli."( The Odorant Receptor-Dependent Role of Olfactory Marker Protein in Olfactory Receptor Neurons.
Dibattista, M; Reisert, J, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
3-isobutyl-1-methylxanthineAn oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.
3-isobutyl-1-methylxanthineAn oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
cytokinins 7-N-glucoside biosynthesis219
cytokinins 9-N-glucoside biosynthesis217

Protein Targets (71)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency11.90470.01846.806014.1254AID624172; AID624417
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.58930.001318.074339.8107AID926
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency21.13170.001530.607315,848.9004AID1224821
mitogen-activated protein kinase 1Homo sapiens (human)Potency15.04370.039816.784239.8107AID995
gemininHomo sapiens (human)Potency16.72920.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.80640.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.80641.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, High-affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)IC50 (µMol)8.10008.10008.10008.1000AID977608
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)31.000031.000031.000031.0000AID977608
Chain A, Phosphodiesterase 9AHomo sapiens (human)IC50 (µMol)500.0000500.0000500.0000500.0000AID977608
Chain A, Class I phosphodiesterase PDEB1Leishmania majorIC50 (µMol)580.0000580.0000580.0000580.0000AID977608
Chain A, High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)IC50 (µMol)698.0000698.0000698.0000698.0000AID977608
Chain A, cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)40.000040.000040.000040.0000AID977608
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase catalytic domain, Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha chimeraHomo sapiens (human)Ki0.00850.00850.00850.0085AID977610
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase catalytic domain, Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha chimeraHomo sapiens (human)Ki0.00850.00850.00850.0085AID977610
Chain A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)IC50 (µMol)117.2000117.2000117.2000117.2000AID977608
Chain A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)IC50 (µMol)117.2000117.2000117.2000117.2000AID977608
Phosphodiesterase Bos taurus (cattle)IC50 (µMol)9.90000.10005.88009.9000AID158421
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)28.00000.00001.77679.2000AID158293; AID1625362; AID1799753
Monocarboxylate transporter 4Homo sapiens (human)IC50 (µMol)970.00000.00100.36840.8600AID678792
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)IC50 (µMol)384.00000.00001.85239.2000AID1625389; AID1799753
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)39.25000.00001.18439.6140AID157309; AID1625383; AID1797375; AID1799753
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)Ki8.50000.00071.07978.5000AID1625388
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)IC50 (µMol)172.33330.00801.16175.6000AID1625391; AID1625392; AID464255
ReninHomo sapiens (human)Ki2.75630.00001.80787.4000AID195542; AID195545
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)IC50 (µMol)9.90000.40002.23759.9000AID158421
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Rattus norvegicus (Norway rat)Ki3.00000.01101.01233.0000AID195545
cAMP-specific 3',5'-cyclic phosphodiesterase 4CRattus norvegicus (Norway rat)Ki3.00000.01101.01233.0000AID195545
cAMP-specific 3',5'-cyclic phosphodiesterase 4BRattus norvegicus (Norway rat)Ki3.00000.01101.01233.0000AID195545
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki3.00000.00020.675810.0000AID195545
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)7.00000.00020.552110.0000AID31403
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki5.72780.00011.20929.9700AID195542; AID195543; AID195545; AID196738; AID31714; AID31860; AID31887
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki5.14170.00030.91969.0000AID195542; AID195543; AID195545; AID196738
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)13.00000.00240.68169.0000AID33406
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki6.15000.00061.353610.0000AID195542; AID195543; AID195545; AID196738; AID33434; AID33897
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)13.00000.00120.48289.0000AID33406
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki6.11500.00021.494010.0000AID195542; AID195543; AID195545; AID196738; AID32862; AID33434; AID33897
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki3.00000.00000.705610.0000AID195545
Adenosine receptor A2aCavia porcellus (domestic guinea pig)Ki8.00000.11002.63858.0000AID30626
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)Ki8.50000.02501.82008.5000AID1625388
cAMP-specific 3',5'-cyclic phosphodiesterase 4ARattus norvegicus (Norway rat)Ki3.00000.01101.01233.0000AID195545
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)IC50 (µMol)3.40000.23002.510510.0000AID158892
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)IC50 (µMol)9.90000.40002.23759.9000AID158421
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)IC50 (µMol)3.40000.00002.14179.2000AID158892
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BRattus norvegicus (Norway rat)IC50 (µMol)0.10000.10000.20000.3000AID179556
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)IC50 (µMol)23.57000.00001.104010.0000AID1381681; AID1421678; AID1707985
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)45.66670.00001.146310.0000AID1352514; AID1625381; AID1799753
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)IC50 (µMol)0.24200.00002.072410.0000AID1625365; AID1797374
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)466.00000.00032.25459.6000AID1207658
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)IC50 (µMol)85.60000.09001.63104.6900AID1381682; AID1421679
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)Ki4.00000.60002.30004.0000AID238298
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)IC50 (µMol)3.40000.23001.98149.0000AID158892
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)IC50 (µMol)37.50000.00031.990110.0000AID1464029; AID1799753
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CRattus norvegicus (Norway rat)IC50 (µMol)0.10000.10000.20000.3000AID179556
Phosphodiesterase Rattus norvegicus (Norway rat)IC50 (µMol)0.10000.10000.20000.3000AID179556
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)Ki4.00000.60002.30004.0000AID238298
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Homo sapiens (human)Kd5.90000.00020.46215.9000AID238055
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2aHomo sapiens (human)Affinity constant5.00000.20006.028610.0000AID33909
Adenosine receptor A2bHomo sapiens (human)Affinity constant5.00000.20006.028610.0000AID33909
Adenosine receptor A1Homo sapiens (human)Affinity constant2.00000.00301.069110.0000AID30353
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (217)

Processvia Protein(s)Taxonomy
negative regulation of cell adhesionPhosphodiesterase Bos taurus (cattle)
negative regulation of angiogenesisPhosphodiesterase Bos taurus (cattle)
negative regulation of lipid catabolic processPhosphodiesterase Bos taurus (cattle)
heart valve developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
ventricular septum developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
aorta developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of inflammatory responsecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
establishment of endothelial barriercGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to mechanical stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cAMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cGMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxinecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of gene expressioncGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of mitochondrion organizationcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
lactate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
pyruvate catabolic processMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transportMonocarboxylate transporter 4Homo sapiens (human)
cAMP catabolic processHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
regulation of DNA-templated transcriptionHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cellular response to epidermal growth factor stimulusHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cAMP-mediated signalingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
positive regulation of cardiac muscle hypertrophycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of nitric oxide mediated signal transductioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cardiac muscle contractioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
relaxation of cardiac musclecGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
signal transductionHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cGMP metabolic processHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cGMP catabolic processHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
positive regulation of long-term synaptic potentiationHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
negative regulation of neural precursor cell proliferationHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cAMP-mediated signalingHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
phototransduction, visible lightCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
retinal cone cell developmentCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
cAMP-mediated signalingCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
visual perceptionCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
regulation of smooth muscle cell apoptotic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cGMP catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
regulation of smooth muscle cell proliferationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
response to amphetamineCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
locomotory behaviorCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
visual learningCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
monocyte differentiationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
dopamine catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
serotonin metabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulusCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
neutrophil homeostasiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
neutrophil chemotaxiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
leukocyte migrationcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to lipopolysaccharidecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesioncGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cellular response to insulin stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesion mediated by integrincGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of lipid catabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cAMP catabolic processHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
cAMP-mediated signalingHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
oocyte maturationcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
lipid metabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
response to xenobiotic stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of meiotic nuclear divisioncGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of apoptotic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
steroid hormone mediated signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of oocyte developmentcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of ribonuclease activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to cGMPcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
apoptotic signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
chemical synaptic transmissioncAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (56)

Processvia Protein(s)Taxonomy
metal ion bindingPhosphodiesterase Bos taurus (cattle)
magnesium ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
zinc ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
TPR domain bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
phosphate ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein homodimerization activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
RNA bindingMonocarboxylate transporter 4Homo sapiens (human)
protein bindingMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
lactate:proton symporter activityMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
kinase bindingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
protein kinase activator activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
metal ion bindingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activityHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
protein bindingHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
metal ion bindingHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
protein bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
cGMP bindingCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
metal ion bindingCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein kinase B bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
metal ion bindingHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
nuclear estrogen receptor activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
estrogen bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (53)

Processvia Protein(s)Taxonomy
membranePhosphodiesterase Bos taurus (cattle)
guanyl-nucleotide exchange factor complexPhosphodiesterase Bos taurus (cattle)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
endoplasmic reticulumcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
Golgi apparatuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
presynaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
synaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial matrixcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
apical plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
lateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
nuclear membraneMonocarboxylate transporter 4Homo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
cytosolHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
extracellular exosomeHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
perinuclear region of cytoplasmHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cytosolHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
nucleusHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cellular_componentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleoplasmHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
endoplasmic reticulumHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
Golgi apparatusHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cytosolHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
plasma membraneHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
ruffle membraneHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
sarcolemmaHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
perikaryonHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
perinuclear region of cytoplasmHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
plasma membraneCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
synaptic vesiclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
postsynaptic densitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
Z disccAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
dendritic spinecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
excitatory synapsecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
endoplasmic reticulumcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
Golgi apparatuscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
guanyl-nucleotide exchange factor complexcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cytosolHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
perinuclear region of cytoplasmHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
nucleusHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
cytosolHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
lysosomeCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
synapsecAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (160)

Assay IDTitleYearJournalArticle
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1625392Inhibition of recombinant human PDE9A2 catalytic domain (181 to 506 residues) expressed in Escherichia coli BL21-CodonPlus cells using [3H]cGMP or [3H]cAMP as substrate incubated for 30 mins by liquid scintillation counting method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID33909Affinity constant for A2 receptor control of adenylate cyclase in adipocytes, heart and brain cells1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID158428Compound was evaluated for potency against c-AMP phosphodiesterase relative to theophylline1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Mesoionic xanthine analogues: phosphodiesterase inhibitory and hypotensive activity.
AID34158Inhibition of adenyl cyclase via P site in adipocytes; Inactive1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID32862Binding affinity for adenosine A2A receptor from rat brain membranes using [3H]CGS-216801993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID1887040Activation of PKA substrate phosphorylation in Wistar rat VSMCs at 100 uM incubated for 60 mins by Western blot analysis2022Journal of natural products, 09-23, Volume: 85, Issue:9
Calofolic Acid-A from
AID1145778Inhibition of phosphodiesterase (peak-1) isolated from pig coronary artery assessed as inhibition of cAMP hydrolysis at 10'-7 to 10'-4 M using 1 uM cAMP substrate in presence of 3% EtOH1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine.
AID218879In vitro vascular relaxation in canine coronary arteries precontracted with prostaglandin F2alpha.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID1421679Inhibition of recombinant human PDE7A using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.
AID225249Inhibition of crude cGMP phosphodiesterase from canine thoracic aorta1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID195542Antagonist binding of 2-chloro-[3H]-adenosine to rat brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID157309Inhibition of PDE5 from platelets2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
AID452089Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po treated 60 mins before carrageenan challenge measured after 90 mins2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
AID233904Selectivity was expressed as the ratio is Ki of adenosine A1 receptor to that of adenosine A2 receptor1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors.
AID30626Compound was evaluated for its ability to antagonise cyclic [3H]AMP accumulation in [3H]adenine-labeled guinea pig cerebral cortical slices.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors.
AID1887045Activation of PKA substrate phosphorylation in isoproterenol-induced Wistar rat VSMCs at 10 uM preincubated for 60 mins followed by isoproterenol stimulation and measured upto 20 mins by Western blot analysis2022Journal of natural products, 09-23, Volume: 85, Issue:9
Calofolic Acid-A from
AID379070Inhibition of MIP1alpha expression in LPS-stimulated human monocytes at 100 uM treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID30353Affinity constant for inhibition of A1 receptor control of adenylate cyclase in adipocytes, heart and brain cells1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID196738Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat fat1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID42825Antagonist binding of N6-cyclohexyl-[3H]-adenosine to bovine brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID678792TP_TRANSPORTER: inhibition of L-Lactate uptake (L-Lactate:30mM) in Xenopus laevis oocytes2000The Journal of physiology, Dec-01, Volume: 529 Pt 2Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
AID379068Inhibition of TNFalpha expression in LPS-stimulated human monocytes at 100 uM treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID33435Binding affinity against Adenosine A2 receptor in rat brain membrane, using [3H]-NECA as the radioligand.1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.
AID379060Inhibition of IL8 expression in LPS-stimulated human monocytes at 100 uM treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID1129268Stimulation of lipolysis in mouse 3T3L1 cells at 0.25 mM after 48 hrs by glycerol release assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Illudins C2 and C3 stimulate lipolysis in 3T3-L1 adipocytes and suppress adipogenesis in 3T3-L1 preadipocytes.
AID1625389Inhibition of recombinant PDE8A1 catalytic domain (480 to 820 residues) (unknown origin) expressed in Escherichia coli BL21-CodonPlus cells using [3H]cGMP or [3H]cAMP as substrate incubated for 15 mins by liquid scintillation counting method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID60818Percent change in heart rate after intravenous administration in anesthetized dogs at 0.3 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID60820Percent change heart rate after intravenous administration in anesthetized dogs at 1.0 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID452091Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip treated 60 mins before carrageenan challenge measured after 90 mins2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
AID1625391Inhibition of recombinant human PDE9A2 catalytic domain (181 to 506 residues) expressed in Escherichia coli BL21-CodonPlus cells using [3H]cGMP or [3H]cAMP as substrate incubated for 15 mins by liquid scintillation counting method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID225246Inhibition of crude cAMP phosphodiesterase from canine cardiac aorta1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID379067Inhibition of PDE4 in human monocytes assessed as elevation of cytosolic cAMP level at 200 uM treated for 30 mins assessed per 10'7 cells by EIA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID158583Inhibition of Phosphodiesterase 2 from pig coronary artery1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Inhibition of cyclic nucleotide phosphodiesterases from pig coronary artery by benzo-separated analogues of 3-isobutyl-1-methylxanthine.
AID1451035Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as adiponectin level at 4 uM measured on day 7 after 48 hrs by ELISA2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID452093Toxicity in Sprague-Dawley rat assessed as gastrointestinal ulceration at 200 mg/kg, po once daily for 5 days2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
AID379058Inhibition of IL1-beta expression in LPS-stimulated human monocytes at 100 uM treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID243443Dissociation constant against Adenosine A1 receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: thermodynamics of cytoplasmic steroid/nuclear receptors in comparison with membrane receptors.
AID1352516Inhibition of bovine brain PDE1 assessed as increase in cAMP levels at 40 uM after 60 mins by BIOMOLGREEN dye-based assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.
AID78489Antagonist binding of N6-cyclohexyl-[3H]-adenosine to guinea pig brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID379059Inhibition of IL6 expression in LPS-stimulated human monocytes at 100 uM treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID1145777Inhibition of phosphodiesterase (peak-1) isolated from pig coronary artery assessed as inhibition of cGMP hydrolysis at 10'-7 to 10'-4 M using 1 uM cGMP substrate in presence of 3% EtOH1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine.
AID1625388Inhibition of recombinant human His6-tagged PDE5A (535 to 786 residues)/PDE6C expressed in Escherichia coli BL21-CodonPlus cells using [3H]cGMP as substrate2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID464255Inhibition of human PDE9A expressed in Escherichia coli BL21 by liquid scintillation counting2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.
AID1056021Competitive inhibition of human recombinant PDE7A1 using [3H]AMP after 20 mins by Lineweaver-Burk plot analysis2013European journal of medicinal chemistry, , Volume: 70Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities.
AID60815Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 1.0 mg/kg (NC<10%)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID452090Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po treated 60 mins before carrageenan challenge measured after 180 mins2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
AID1352513Inhibition of recombinant human PDE4D expressed in Escherichia coli assessed as increase in cAMP levels at 40 uM after 60 mins by BIOMOLGREEN dye-based assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.
AID452092Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip treated 60 mins before carrageenan challenge measured after 180 mins2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
AID31887Binding affinity for adenosine A1 receptor from rat brain membranes using [3H]PIA as radioligand1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.
AID195543Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID33897Antagonism of N-ethylcarboxamido adenosine-stimulated adenylate cyclase associated with stimulation of Adenosine A2 receptor of rat PC12 membranes1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Imidazodiazepinediones: a new class of adenosine receptor antagonists.
AID184683Minimal effective dose in an rat anti-immobility effect using behavioral despair test1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID452088Inhibition of PDE12009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
AID1887056Activation of PKA in isoproterenol-induced Wistar rat VSMCs assessed as increase in intracellular cAMP concentration at 100 uM measured 20 mins after ISO stimulation2022Journal of natural products, 09-23, Volume: 85, Issue:9
Calofolic Acid-A from
AID1887041Activation of PKA substrate phosphorylation in isoproterenol-induced Wistar rat VSMCs at 100 uM preincubated for 60 mins followed by ISO stimulation and measured upto 30 mins by Western blot analysis2022Journal of natural products, 09-23, Volume: 85, Issue:9
Calofolic Acid-A from
AID232222Selectivity for A2 and A1 receptors was evaluated1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.
AID31881Binding affinity at Adenosine A1 receptor in rat brain cortical membrane using [3H]N6-R-phenylisopropyladenosine (R-PIA) as radioligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID60812Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 0.1 mg/kg (NC<10%)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID1707985Inhibition of recombinant human PDE4B using 5'-cGMP as substrate measured after 90 mins by colorimetric assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition.
AID158892Inhibition of [Ca(2+)]/calmodulin dependent phosphodiesterase PDE 1 of human lung1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID218881In vitro vascular relaxation in canine mesenteric veins precontracted with phenylephrine.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID31860Binding affinity for Adenosine A1 receptor from rat brain using [3H]-PIA as radioligand1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Imidazodiazepinediones: a new class of adenosine receptor antagonists.
AID31861Binding affinity against Adenosine A1 receptor in rat brain membrane, using [3H]N6-cyclohexyladenosine as the radioligand1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.
AID1625362Inhibition of human C-terminal His6-tagged PDE2A1 (215 to 900 residues) expressed in sf21 cells2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID1145775Inhibition of phosphodiesterase (peak-1) isolated from pig coronary artery assessed as inhibition of cAMP hydrolysis using 1 uM cAMP substrate in presence of 3% Me2SO1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID179556Evaluated for Ca++ dependent phosphodiesterase activity. 1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID158421In vitro inhibition of bovine heart phosphodiesterase (PDE I)1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Mesoionic xanthine analogues: phosphodiesterase inhibitory and hypotensive activity.
AID1421678Inhibition of recombinant human PDE4B using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID60817Percent change heart rate after intravenous administration in anesthetized dogs at 0.1 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID179558Evaluated for Ca++ independent phosphodiesterase activity. 1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID238055Dissociation constant against Adenosine A1 receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: thermodynamics of cytoplasmic steroid/nuclear receptors in comparison with membrane receptors.
AID1726630Inhibition of recombinant human PDE-4B expressed in Escherichia coli at 20 uM using cAMP as substrate incubated for 60 mins by PDE4 assay kit method relative to control2021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors.
AID1145776Inhibition of phosphodiesterase (peak-2) isolated from pig coronary artery assessed as inhibition of cAMP hydrolysis using 1 uM cAMP substrate in presence of 3% Me2SO1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine.
AID1625365Inhibition of human His-tagged PDE3B catalytic domain expressed in Escherichia coli BL21(DE3) pLysS cells2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID158293Inhibition of cyclic GMP sensitive phosphodiesterase PDE 2 of human lung1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID1625383Inhibition of PDE5A (unknown origin)2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID1451034Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as adiponectin level at 20 uM measured on day 7 after 48 hrs by ELISA2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID58413Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 0.1 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID195545Antagonist binding of rN6-cyclohexyl-[3H]adenosine to rat brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID58416Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 0.3 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID379069Inhibition of IL10 expression in LPS-stimulated human monocytes at 100 uM treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID238298Inhibition of human phosphodiesterase 72005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
AID158305Inhibition of low Km cAMP phosphodiesterase PDE III of human lung1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID1129548Cytotoxicity against human HuH7 cells at 1 mM after 144 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Bisphosphonate prodrugs: synthesis and biological evaluation in HuH7 hepatocarcinoma cells.
AID1464029Inhibition of human PDE3A by HTRF assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo[e][1,3]oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation.
AID1145779Inhibition of phosphodiesterase (peak-2) isolated from pig coronary artery assessed as inhibition of cAMP hydrolysis at 10'-7 to 10'-4 M using 1 uM cAMP substrate in presence of 3% EtOH1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine.
AID1207658Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1381682Inhibition of human GST-tagged PDE7A expressed in baculovirus infected Sf9 insect cells using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
AID158414Inhibitory concentration against phosphodiesterase from bovine heart2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Visual detection of AMP and real-time monitoring of cyclic nucleotide phosphodiesterase (PDE) activity in neutral aqueous solution. Chemosensor-coupled assay of PDE and PDE inhibitors.
AID1145774Inhibition of phosphodiesterase (peak-1) isolated from pig coronary artery assessed as inhibition of cGMP hydrolysis using 1 uM cGMP substrate in presence of 3% Me2SO1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine.
AID1352514Inhibition of recombinant human PDE4D expressed in Escherichia coli assessed as increase in cAMP levels after 60 mins by BIOMOLGREEN dye-based assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.
AID33406Evaluated for the binding affinity towards the Adenosine A2 receptor in corpora striata of rats using [3H]NECA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID158581Inhibition of Calmodulin Sensitive Phosphodiesterase 1 from pig coronary artery1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Inhibition of cyclic nucleotide phosphodiesterases from pig coronary artery by benzo-separated analogues of 3-isobutyl-1-methylxanthine.
AID31714Ability to inhibit binding of 1 nM [3H]cyclohexyladenosine to adenosine A1 receptor in rat cerebral cortical membranes1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors.
AID58418Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 1.0 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID1625381Inhibition of PDE4D (unknown origin)2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID1625371Inhibition of Leishmania major PDEB1 catalytic domain (582 to 940 residues) expressed in Escherichia coli BL21-CodonPlus cells using [3H]cGMP or [3H]cAMP as substrate incubated for 15 mins by liquid scintillation counting method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID219084In vitro increase in contractile force in ferret papillary muscle strips.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID60814Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 1.0 mg/kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
AID31403Binding affinity towards the adenosine A1 receptor in cerebral cortices of Sprague-Dawley male rats using [3H]CHA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID1381681Inhibition of human GST-tagged PDE4B expressed in baculovirus infected Sf9 insect cells using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
AID30807Binding affinity against Adenosine A2 receptor in rat striatal membranes using [3H]5'-(N-ethylcarboxamido)-adenosine (NECA) as the ligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID33434Binding affinity for Adenosine A2 receptor from rat striatum using [3H]NECA as radioligand1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Imidazodiazepinediones: a new class of adenosine receptor antagonists.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2009The EMBO journal, Nov-18, Volume: 28, Issue:22
Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2005The Journal of biological chemistry, Sep-02, Volume: 280, Issue:35
Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
AID1345685Human A1 receptor (Adenosine receptors)1994The Journal of biological chemistry, Dec-23, Volume: 269, Issue:51
Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1797374PDE SPA Enzyme Inhibition Assay from Article 10.1021/bi049868i: \\Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.\\2004Biochemistry, May-25, Volume: 43, Issue:20
Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
AID1797375Enzymatic Assay from Article 10.1074/jbc.M512527200: \\Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.\\2006The Journal of biological chemistry, Jul-28, Volume: 281, Issue:30
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
AID1799753Enzymatic Assay from Article 10.1074/jbc.M111.326777: \\Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.\\2012The Journal of biological chemistry, Apr-06, Volume: 287, Issue:15
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2007Molecular microbiology, Nov, Volume: 66, Issue:4
Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2007Molecular microbiology, Nov, Volume: 66, Issue:4
Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1811Experimentally measured binding affinity data derived from PDB2004Proceedings of the National Academy of Sciences of the United States of America, Jun-29, Volume: 101, Issue:26
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2004Proceedings of the National Academy of Sciences of the United States of America, Jun-29, Volume: 101, Issue:26
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2011PloS one, Mar-31, Volume: 6, Issue:3
Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2009Proceedings of the National Academy of Sciences of the United States of America, Oct-27, Volume: 106, Issue:43
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2008Biochemistry, Dec-02, Volume: 47, Issue:48
Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2004The Journal of biological chemistry, Mar-26, Volume: 279, Issue:13
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,027)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901841 (36.62)18.7374
1990's2027 (40.32)18.2507
2000's828 (16.47)29.6817
2010's291 (5.79)24.3611
2020's40 (0.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 5.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index5.72 (24.57)
Research Supply Index8.55 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (5.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (0.10%)5.53%
Reviews33 (0.64%)6.00%
Case Studies4 (0.08%)4.05%
Observational0 (0.00%)0.25%
Other5,106 (99.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]